Ed Silverman over at Pharmalot features the story that came out in the Wall Street Journal this week, about Genentech’s Lucentis competing with its sibling drug, Avastin, in the treatment of macular degeneration. The NIH is planning to sponsor a head-to-head trial.
More interesting stuff on Avastin – indications that it may be effective with brain tumors. Then of course there’s the late breaking news that half the recommended dose of Avastin seems to be just as effective as the full dose in treating lung cancer.
I’m sure there have been other interesting news tidbits this week, but I’m in a hurry today!